Co-Diagnostics Showcases PCR Platform at WHX Labs Dubai

Co-Diagnostics, Inc. (Co-Dx; Salt Lake City, UT, USA), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is showcasing its transformative PCR platform at WHX Labs Dubai, taking place February 10–13, 2026.

Co-Dx's participation at the event follows the formation of its recently announced joint venture, CoMira Diagnostics, with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia. CoMira Diagnostics was formed to localize manufacturing and distribution of Co-Diagnostics' technologies and intellectual property across Saudi Arabia and 18 additional countries in the Middle East and North Africa ("MENA"). The event provides an opportunity for Co-Dx to engage with regional stakeholders and support its strategy to expand access to high-quality molecular diagnostics throughout the region, including the company's upcoming Co-Dx PCR platform, currently in clinical studies in the United States.

Image: The Co-Dx PCR platform brings lab-quality PCR testing to point-of-care settings (Photo courtesy of Co-Dx)

Attendees interested in learning more about the Co-Dx's products can visit Co-Dx and CoMira representatives at the World Trade Center Utah booth. World Trade Center Utah is a member of the World Trade Centers Association founded in 2006 with the goal of helping Utah companies increase revenue and create jobs by expanding international sales, attracting foreign investment, and facilitating international partnerships.

The Co-Dx PCR platform is a portable, real-time molecular diagnostics system designed to bridge the gap between high-quality laboratory testing and the convenience of at-home or point-of-care (PoC) settings. The platform aims to democratize access to "gold-standard" PCR technology by making it compact, affordable, and user-friendly. It delivers clinical-grade results in approximately 30 minutes, providing a rapid turnaround that eliminates the need for centralized laboratory processing. The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, all associated tests and licensed applications of the technology) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

Related Links:
Co-Diagnostics, Inc.